Comparison of Authentic and Suspect Pharmaceuticals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Comparison of Authentic and Suspect Pharmaceuticals
The authors applied near-infrared (NIR) spectrophotometry to assess whether eight drug products were authentic or counterfeit.


Pharmaceutical Technology
Volume 33, Issue 8, pp. 46-52


Figure 9. Near-infrared spectra of Viagra 100 mg test and reference products.
NIR comparison also agreed with simple visual inspection for test Cialis 50 mg (ρm = 0.303 and δa = 21.1 over the 400–2500-nm range). Disintegration testing of test Cialis 50 mg further supported the thesis that the product was counterfeit. Three individual tablets each required more than 15 min (15:20, 16:34, and 17:35 min) to disintegrate. Reference Cialis 20 mg disintegrated in less than 5 min (3:57, 3:57, and 4:10 min for each of three tablets).

Test Norvasc 10 mg was the exceptional product. Simple visual inspection indicated that the product was authentic, but NIR could not determine its authenticity (ρm = 1.07 and δa = 54.4 over the 400–2500-nm range). TLC results from the amlodipine besylate products and API indicated that the test Norvasc 10 mg product contained the labeled drug.

Comparison of the authentic generic amlodipine besylate 10 mg to the reference. Figure 7 plots the NIR spectra of authentic generic amlodipine besylate 10 mg. Like test Norvasc 10 mg, generic amlodipine besylate 10 mg exhibited a spectrum that was different from that of the reference (i.e., ρm > 0.15 and δa > 15). Generic amlodipine besylate 10 mg was manufactured by Mylan Laboratories. Comparing the spectral differences of the Mylan product and the test Norvasc 10 mg product with their references showed that the Mylan product differed from the reference in a pattern similar to the way the Hong Kong product differed from its reference. Each showed a baseline shift, but provided similar peak positions to references. In spite of the larger ρm and δa values for generic amlodipine besylate 10 mg and test Norvasc 10 mg, the generic product was presumed authentic, and test Norvasc 10 mg could be authentic. TLC results showed a single spot from test and reference Norvasc 10 mg products, as well as from the Mylan product, that agreed with the TLC results from amlodipine besylate API.

Conclusion

The authors concluded that test Cialis 20 mg, test Lamisil 250 mg, test Levitra 20 mg, test Norvasc 5 mg, test Viagra 50 mg, and test Viagra 100 mg were authentic and test Cialis 50 mg and test Norvasc 10 mg were potentially counterfeit. Generic amlodipine besylate 10 mg did not provide a spectrum that could be described as similar to that of the reference product, although no evidence supports the thesis that this product is counterfeit.

These results indicated that NIR is a viable approach for the quick assessment of potentially counterfeit products, particularly because NIR spectra are sensitive to both composition and physical properties. Results also indicated that initial field testing for counterfeits can be accomplished with a handheld NIR spectrophotometer. To minimize incorrect NIR-based conclusions about products, NIR spectra should be interpreted with care.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here